FIELD: chemistry.
SUBSTANCE: invention relates to compounds of general formula (I), in which (i) R1 denotes C1-C6-alkyl or hydrogen; and R2 denotes hydrogen or a -R7, -Z-Y-R7, -Z-NR9R10, -Z-CO-NR9R10, -Z-NR9-C(O)O-R7 or -Z-C(O)-R7 group; and R3 denotes an undefined pair or C1-C6-alkyl; or (ii) R1 and R3 together with a nitrogen atom with which they are bonded form a 5-6-member heterocycloalkyl ring; and R2 denotes an undefined pair or a -R7 , -Z-Y-R7 group; or (iii) R1 and R2 together with a nitrogen atom with which they are bonded form a 6-member heterocycloalkyl ring, where said ring is substituted with a -Y-R7 group, and R3 denotes an undefined pair or C1-C6-alkyl; R4 and R5 are independently selected from a group consisting of phenyl, C3-C6-cycloalkyl; R6 denotes -OH, C1-C6-alkyl, C1-C6-alkoxy or a hydrogen atom; A denotes an oxygen or sulphur atom; X denotes a C1-C6-alkylene group; R7 denotes C1-C6-alkyl, phenyl, phenyl(C1-C6-alkyl)-, dihydrobenzofuran or pyridine, where any phenyl in group R7 can be optionally substituted with one or two groups independently selected from halogen, aminoacyl, C1-C6-alkoxycarbonyl, aminosulphonyl, C1-C6-alkyl, C1-C6-alkylamino-C1-C6-alkyl, -COOH; and any pyridine in group R7 can be optionaly substituted with C1-C6-alkyl; R8 denotes C1-C6-alkyl or a hydrogen atom; Z denotes a C1-C10-alkylene or C2-C10-alkenylene group; Y denotes a bond or an oxygen atom; R9 and R10 independently denote a hydrogen atom, C1-C6-alkyl group, isoxazole or 8-hydroxy-1H-quinolin-2-one-(C1-C6-hydroxyalkyl); and pharmaceutically acceptable salts thereof. The invention also relates to a pharmaceutical composition having activity with respect to M3 muscarinic receptor; use of the compounds of formula (I) to produce a medicinal agent for treating and a method of treating diseases or conditions in which M3 muscarinic receptor activity is involved.
EFFECT: compounds of given formula have activity with respect to M3 muscarinic receptor.
26 cl, 8 dwg, 91 ex
Title | Year | Author | Number |
---|---|---|---|
DERIVANTS OF BICYCLO[2, 2, 1] HEPT-7-YLAMINE AND THEIR APPLICATIONS | 2006 |
|
RU2442771C2 |
NEPRILYSIN INHIBITORS | 2013 |
|
RU2663618C2 |
TRICYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND USING THEM FOR TREATING IMMUNOLOGICAL AND ONCOLOGICAL COMPOUNDS | 2009 |
|
RU2545023C9 |
SUBSTITUTED BENZENE COMPOUNDS | 2012 |
|
RU2629118C2 |
ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | 2012 |
|
RU2632193C2 |
N-7 SUBSTITUTED PURINES AND PYRAZOLOPYRIMIDINES, COMPOSITIONS THEREOF AND METHODS FOR USE | 2010 |
|
RU2515541C2 |
OXYSTEROLS AND THEIR APPLICATION METHODS | 2017 |
|
RU2754130C2 |
2,6-SUBSTUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | 2005 |
|
RU2417990C2 |
NON-LINEAR SELF-SPLITTING LINKERS AND THEIR CONJUGATES | 2017 |
|
RU2755899C2 |
PYRIMIDINE DERIVATIVES AND USING THEM IN TREATING RESPIRATORY DISEASES, SUCH AS COPD | 2011 |
|
RU2581839C2 |
Authors
Dates
2011-12-20—Published
2006-08-08—Filed